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ABSTRACT 
Objective: The objective of this study was to evaluate the beneficial effect of topical applications of 20% sunflower seed oil (SSO) in decreasing the 
transepidermal water loss (TEWL) and scoring of atopic dermatitis (SCORAD) index value in mild atopic dermatitis (AD) pediatric patients in 
Bandung, Indonesia.  
Methods: This was a randomized study involving 20 children with mild AD (SCORAD<25) in Bandung, Indonesia. They were divided into 2 groups: 
the experimental group treated with 20% SSO cream and the control group treated with a common moisturizing cream for four weeks. The TEWL 
score including SCORAD index was evaluated at baseline, week 1, week 2, and week 4. 
Results: A total of 20 participants completed the study. In the first week, the control group had TEWL score decrement by 36.62% while the 
experimental group by 28.89% (p=0.88). In the fourth week, the TEWL decrements of the experimental and control group were by 56.94% and 
52.50%, respectively (p=0.20), and this was followed by an improvement of SCORAD index in both treatment groups. 
Conclusion: The 20% SSO cream has a beneficial effect in decreasing the TEWL score and improving SCORAD indices. Therefore, it can be 
considered as an alternative treatment for mild AD among children. 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (





Atopic dermatitis (AD) is an inflammatory skin condition 
characterized by intense pruritus in a waxing and waning course [1]. 
It affects 10-20% children and 1-3% adults worldwide, with a female 
to male ratio of 1.3:1.1 [1]. In 2013, the prevalence of AD according 
to Pediatric Dermatology Clinic data from five tertiary referral 
hospitals in Indonesia was 11.8% [2]. 
A complex interaction between genetic, immune system 
dysregulation and environmental factors have been documented as 
the pathogenesis of AD [2]. Filagrin mutation decreased ceramide, 
and increased endogenous proteolytic enzymes, often result in 
increased transepidermal water loss (TEWL) [3]. In the case of a 
damaged skin barrier function, TEWL normally increases and 
facilitates the penetration of allergens and microbes into the skin 
[4]. Jensen et al. reported an increase of TEWL in AD patients, both 
in the lesional and non-lesional skin [5]. Scoring of atopic dermatitis 
(SCORAD) is a clinical tool used to assess the extent and severity of 
AD, which can be used before and after treatment to determine its 
effectiveness. It measures the of the extent of skin lesions, the 
intensity of the disease, and subjective complaints [6]. 
Natural moisturizing factor (NMF) deficiency has been observed 
in AD patient’s skin. Natural moisturizing factor (NMF) 
maintains the TEWL in the stratum corneum by serving as 
humectant [7]. Peroxisome proliferator-activated receptor-alpha 
(PPAR-α) might improve skin barrier function by regulating the 
lipid metabolism in the skin and stimulating keratinocyte 
differentiation, whose expression was usually reduced in AD [8, 
9]. The use of moisturizer in AD patients may improve the 
function of the skin barrier [10]. Nevertheless, its high cost can 
be a burden for low-income society. Therefore, an effective and 
cost-effective moisturizer, like sunflower seed oil (SSO) cream, is 
urgently needed. 
Sunflower (Helianthus annus) seeds have been found to contain 
carbohydrates, proteins, fats, calcium, flavonoids, alkaloids, and 
many other phytochemicals which are responsible for their 
beneficial pharmacological properties [11]. Sunflower seed oil (SSO) 
is an oil produced from these seeds, contains a high level of essential 
fatty acids, especially linoleic acid, which improves the skin barrier 
and thus frequently used in infant skin care [12]. It is affordable, 
safe, and attainable in Indonesia. Various studies on SSO have shown 
that it has a virtuous effect in patients with normal skin as well as in 
AD patients [12, 14]. SSO exerts its anti-inflammatory effect by 
binding with PPAR receptor in the surface of keratinocytes [15, 16]. 
Various studies on SSO in both AD and non-AD child population have 
given evidence of its effectiveness in lowering the TEWL scores [14, 
15]. However, to the best of the authors’ knowledge, there has been 
no study comparing SSO with common moisturizers. 
 
Table 1: 20% SSO cream formula 
20% SSO cream formula 
Refined 20% sunflower seed oil  
Cetostearyl alcohol 10% 
Cetomacrogol 10% 
Petroleum jelly 5% 
Potassium sorbate 0.1% 
Propilen glycol 7.5% 
Citrus fragrance qs 
Aquadest ad 100 gr 
 
MATERIALS AND METHODS 
Material and preparation of drugs 
The 20% SSO cream used in this study was made by pharmacists in 
Bandung Institute of Technology, Indonesia and had undergone 
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product animal testing prior to the experiment. The formula is 
presented in table 1. Meanwhile, the control product cream was 
common moisturizing lotions, which were repackaged in uniform 
opaque plastic pots. 
Study design 
This randomized, double-blind trial, in children with mild AD, was 
conducted in two locations: in the outpatient clinic of Dermatology 
Department in Dr. Hasan Sadikin Hospital Bandung and Sejahtera 
Elementary School Bandung. This study had been approved by the 
Health Research Ethics Committee, Faculty of Medicine, Universitas 
Padjadjaran/Dr. Hasan Sadikin Hospital Bandung, West Java, Indonesia 
with ethical clearance number: LB.04.01/A05/EC/296/IX/2016. 
Informed consent from one parent or caregiver and the assent of 
children were likewise secured prior to treatment. 
Subject 
The enrolled participants were those patients in the age range of 7–
12 y of age with mild AD, who met the Hanifin and Rajka criteria and 
had SCORAD index of<25, were enrolled. The exclusion criteria 
were: (1) those with known hypersensitivity reactions to SSO cream 
and control product cream, (2) those who have used moisturizer 
other than the given treatment or any medication on both arms, legs, 
and lesions within one week prior to the study, (3) those who have 
taken anti-inflammatory and antihistamine drugs 2 w before and 
during the study, (4) those with other co-existing another skin 
diseases in the area that were going to be treated, (5) those with co-
existing recurrent atopic disease, (6) those who had AD with 
secondary bacterial infection. 
Procedures 
Twenty children with AD who met the criteria were randomly 
assigned into two groups: group I (9 participants) who were treated 
with 20% SSO cream and group II (11 participants) who were 
treated with a common commercial moisturizer. Both creams passed 
the animal testing and were repacked in an opaque container. They 
were marked with random labels and only research assistant knew 
the contents of each label. Both researchers and subjects of the study 
were blinded to the content of the creams. TEWL was measured on 
the mid-volar of the lower arm, both popliteal fossa, and skin lesions. 
The cream was then applied on both arms, both limbs, and in AD 
lesions (if present). Patient-applied the cream twice daily at home in 
the same instructed locations. No other creams or lotions may be 
used on the observation area. Clinical assessments were performed 
at baseline (day 0), and on follow up on week 1 (day 7), week 2 (day 
14), and week 4 (day 28). 
Outcome measures 
The TEWL score was measured at baseline, week 1, week 2, and 
week 4 using the Tewameter TM 300®
Statistical methods 
at four regions (head/neck, 
trunk, upper and lower limbs). On each visit, patients were observed 
for any adverse effect, which, if found, would be recorded. The 
SCORAD index was measured at every visit.  
Paired t-test was used to compare the TEWL scores. Meanwhile, the 
Mann-Whitney test was used to compare the mean of the TEWL 
scores and SCORAD index between the two groups. Results were 
considered to be significant if the p-value was less than 0.05. 
RESULTS 
Demographic profile 
In both groups, the age ranges from 7 to 12 y old. The mean age for 
SSO cream group and control cream group were 8.56±1.51 y and 
9.45±2.70 y respectively. Sixty-five percents (13 out of 20) of the 
patients were female. 
 
Table 2: Demographic data in both groups 
Variables SSO 20% Control cream p-value 
(n = 9)  (n = 11) 
Age (years) 


















*p-value>0.05 compared with the control group using paired t-test., **p-value>0.05 compared with the control group using fisher’s exact test. 
 
TEWL scores 
The TEWL scores in both treatment groups were measured on 
the right arm, left arm, right leg, and left leg. There was a 
reduction of TEWL scores in both treatment groups. The average 
TEWL score was 17.26 in SSO cream group and 16.31 in the 
control cream group at baseline; 12.26 in the SSO cream group 
and 10.32 in control cream group on week 1; 8.93 in the SSO 
cream group and 8.69 in the control cream group on week 2; 
6.67 in the SSO cream group and 7.74 in the control cream group 
on week 4, as presented in table 3. The paired t-test showed that 
TEWL scores did not differ significantly between both groups at 
baseline (p=0.827), week 1 (p=0.481), week 2 (p=0.899), and 
week 4 (p=0.472). 
 
Table 3: Average of TEWL Scores after the application of SSO cream and control product cream 
Group Location Time 
Baseline Week 1 Week 2 Week 4 


















































p-value   0.827 0.481** 0.899** 0.472** ** 
**p-value>0.05 compared with the control group using paired t-test  
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TEWL scores decrement  
The TEWL score decrement (∆) was measured from four 
different locations. The average TEWL scores decrement (∆) was 
4.98 in the SSO cream group and 5.97 in the control cream group 
after 1 w; 8.45 in the SSO cream group and 7.61 in the control 
cream group after 2 w; 9.83 in the SSO cream group and 8.56 in 
the control cream group after 4 w as presented in table 4. The 
Mann Whitney test showed that the average TEWL score 
decrement was not significantly different between both groups 
after 1 w (p=0.882), after 2 w (p=0.882), and after 4 w 
(p=0.2052). 
 
Table 4: Average TEWL Scores after application of SSO cream and control product cream 
Group Timeline 
Δ Baseline– week 1 Δ Baseline-week 2 Δ Baseline– week 4 
SSO 20% 4.98 8.45 9.83 
Control  5.97 7.61 8.56 
P-value 0.882** 0.882** 0.941** 
**p-value>0.05 compared with the control group using Mann-Whitney test. 
 
Scorad  
A trend of decreasing SCORAD index was observed in both groups 
throughout the treatment session. Reductions of the SCORAD index 
were 100% in both groups. The SCORAD indices in the SSO cream 
group were 7.23, 2.45, 0.61, and 0, whereas in the control cream 
group were 9.33, 4.36, 1.87, and 0 on the baseline, week 1, week 2, 
and week 4, respectively. This considerable improvement in 
SCORAD index was observed in both groups, as presented in table 5. 
 
Table 5: Mean SCORAD among SSO 20% dan control group 
Group Time  
Baseline  Week 1  Week 2  Week 4 
20% SSO  7.23 2.45 0.61 0 
Control  9.33 4.36 1.87 0 
p-value 0.456 0.412 0.131** 1.000 ** 
**p-value>0.05 compared with the control group using Mann-Whitney test 
 
Adverse effects 
There were no adverse reactions reported by either both groups in 
this study. 
DISCUSSION 
The clinical manifestation of AD appeared at the age of 6 mo in forty-
five percent of cases, and about eighty-five percent of AD cases were 
found before the age of 5 y [9]. In this study, the age of the 
participants with mild AD ranged from 2-12 y old, and the mean age 
was 8.56±1.51 y in the SSO cream group, and 9.45±2.70 y in the 
control cream group. Resecach showed that AD is slightly more 
common in women than in men with 1.3:1.0 ratio [13]. In this study, 
there were 13 girls (65%) and 7 boys (35%) with a ratio of 1.85:1.0. 
This ratio is consistent with worldwide prevalence [1]. 
Sunflower seed oil is an occlusive moisturizer and has emollient 
properties [15]. It has a high content of essential fatty acids (EFA), 
especially linoleic acid which could increase the skin barrier [16-18]. 
Linoleic acid content in SSO can be converted into arachidonic acid, a 
precursor of prostaglandin E2 (PGE2), which is a known modulator 
of cutaneous inflammation [12]. In human keratinocytes, PPAR-α 
activators, including linoleic acid, have a regulatory effect by 
increasing involucrin and transglutaminase protein [15, 16]. 
The effect of SSO cream in decreasing TEWL was demonstrated in 
previous randomized controlled trials, and it was postulated to have 
anti-inflammatory activity, making it an effective treatment to AD 
[13]. Study done by Danby et al. (2012) revealed that SSO can 
maintain the integrity of the stratum corneum, repair the skin 
barrier, and decrease the TEWL value [14]. This was confirmed by 
Husna’s study (2012), which revealed that SSO application on the 
adult forearm could reduce the TEWL value [19]. 
In this present study, the efficacy of 20% SSO cream as a moisturizer 
to treat mild AD was compared with the control product as indicated 
by the decrement of TEWL and SCORAD score decrement. Both 
groups demonstrated a decreasing trend in both TEWL and SCORAD 
indices (table 4 and 5). Twenty percent of SSO cream decreased 
TEWL score by 28.89%, 48.99%, and 56.94% in week 1, 2, and 4 
respectively. On the other hand, control product cream decreased 
TEWL score by 36.62% on week 1, 46.68% in week 2 and 52.54% at 
the end of the study period. Statistical analysis showed that the 
average TEWL score decrement was not significantly different 
between both groups. In the SSO 20% cream group, the SCORAD 
indices plummeted from 7.23 (baseline) to 0 (week 4), whereas in 
the controlled group, from 9.33 (baseline) to 0 (week 4). These 
results showed that the ability of 20% SSO cream to decrease TEWL 
and improve SCORAD indices is comparable with the control 
product cream in treating mild cases of AD. The limitation of this 
study was the relatively short follow-up time (4 w), which may not 
be able to observe late adverse effects of 20% SSO cream as a 
moisturizer. 
CONCLUSION 
Twenty percent SSO cream has a comparable efficacy compared with 
the control product in decreasing the TEWL and SCORAD index 
among children with mild AD. Further studies with larger samples 
are required, but this study demonstrated that 20% SSO cream can 
be considered as an alternative moisturizer in the treatment of mild 
AD due to its low cost, beneficial effect, and minimal side-effect. 
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